FDA Panel Votes In Favor Of J&J' DARZALEX FASPRO For High-Risk Smoldering Multiple Myeloma Treatment

An FDA advisory committee voted 6-2 in favor of Johnson & Johnson's DARZALEX FASPRO for treating high-risk smoldering multiple myeloma (HR-SMM) in adults. The recommendation stems from the Phase 3 AQUILA study, which assessed the drug's efficacy and safety versus active monitoring. While the FDA will make the final decision on approval, this positive vote signals potential market expansion for DARZALEX FASPRO in an earlier stage of multiple myeloma treatment.

Analysis

Johnson & Johnson (JNJ) has received a favorable, albeit non-binding, recommendation from the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) regarding its drug DARZALEX FASPRO for the treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM). The committee voted 6-2 in favor of the drug's benefit-risk profile, a decision based on data from the Phase 3 AQUILA study, which evaluated the efficacy and safety of DARZALEX FASPRO versus standard of care active monitoring. According to the report, JNJ's application for this specific indication was submitted to the FDA in November 2024. While the ODAC's recommendations are not binding and the final approval authority rests with the FDA, this positive outcome, associated with a positive sentiment score of 0.4 and an optimistic tone, suggests a potential market expansion for DARZALEX FASPRO into an earlier stage of multiple myeloma treatment. This development is viewed with a moderate market impact score of 0.3, likely reflecting investor anticipation of the FDA's definitive ruling, which will be crucial for JNJ's oncology franchise.

Key Decisions for Investors

• Investors should view the positive ODAC vote for Johnson & Johnson's DARZALEX FASPRO as an encouraging interim development that could de-risk the path towards a label expansion.
• It is crucial to monitor the FDA's final decision on the approval of DARZALEX FASPRO for HR-SMM, as this will be the primary catalyst determining the drug's expanded market access and commercial potential.
• A successful FDA approval would represent a significant advancement for JNJ's oncology portfolio, potentially contributing to future revenue growth and warranting a re-evaluation of JNJ's outlook in this segment.